PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma

1. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.10.3389/fimmu.2016.00550514952328018338 Search in Google Scholar

2. Hoesli R, Birkeland AC, Rosko AJ et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol. 2018; 77:83-89.10.1016/j.oraloncology.2017.12.003589710329362129 Search in Google Scholar

3. Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clin Cancer Res. 2016;22(3):704-713.10.1158/1078-0432.CCR-15-154326408403 Search in Google Scholar

4. Ismail M, Wakiel HE l., Ghany DA, Shakweer MM, Lotfy A, Gaballah AM. 132P - Correlation between tumour infiltration lymphocyte and PDL-1 expression in laryngeal cancer and its prognostic significance: A prospective, non-interventional trial. Ann Oncol. 2019;30:xi49.10.1093/annonc/mdz452.003 Search in Google Scholar

5. Jia YQ, Yang B, Wen LL, Mu WX, Wang Z, Cheng B. Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. Aging (Albany NY). 2019;11(2):501-522.10.18632/aging.101756636699030668545 Search in Google Scholar

6. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.10.1038/s41598-017-17204-5571511029203879 Search in Google Scholar

7. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.10.3389/fimmu.2016.00550 Search in Google Scholar

8. IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. Search in Google Scholar

9. Karpathiou G, Casteillo F, Giroult JB, et al. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immunosuppressive pathways and clinicopathologic characteristics. Oncotarget. 2017;8(12):19310-19322.10.18632/oncotarget.14242538668628038471 Search in Google Scholar

10. Cojocaru Oana, Aschie Mariana, Mocanu Liliana, Baltatescu Gabriela IzabelaLaryngeal primary malignant melanoma: a case report, Rom J Morphol Embryol 2015, 56(4):1513–1516 Search in Google Scholar

11. Harasymczuk M, Gooding W, Kruk-Zagajewska A, Wojtowicz J, Dworacki G, Tomczak H, et al. Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy. Eur Arch oto-rhino-laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology - Head Neck Surg. 2013 Mar;270(3):1105–14.10.1007/s00405-012-2117-1381809422865105 Search in Google Scholar

12. Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3ţ, CD4ţ and CD8ţ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast., Indian J Med Res 2014;140:361–9. Search in Google Scholar

13. Badoual C. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clin Cancer Res. 2006; 12: 465–72.10.1158/1078-0432.CCR-05-188616428488 Search in Google Scholar

14. Rittà M, Landolfo V, Mazibrada J, De Andrea M, Dell’Oste V, Caneparo V, Peretti A, Giordano C, Pecorari G, Garzaro M, Landolfo S. Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer. New Microbiol. 2013; 36: 133–44. Search in Google Scholar

15. Zandberg DP, Strome SE. The role of the PD-L1/PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncology. 2014; p. 627–32.10.1016/j.oraloncology.2014.04.00324819861 Search in Google Scholar

16. Takada K, Toyokawa G, Okamoto T, Akamine T, Takamori S, Katsura M, et al. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria. Anticancer Res. 2016 Jul;36(7):3409–12. Search in Google Scholar

17. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013; 73: 1733–41.10.1158/0008-5472.CAN-12-2384360240623288508 Search in Google Scholar

18. Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT, Chen CJ. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One. 2015; 10: e0142656.10.1371/journal.pone.0142656464296726562534 Search in Google Scholar

19. Cho YA, Yoon HJ, Lee J Il, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011; 47: 1148–53.10.1016/j.oraloncology.2011.08.00721911310 Search in Google Scholar

20. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28:682–8.10.1007/s12032-010-9515-220373055 Search in Google Scholar

21. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One. 2013;8(6):e65821.10.1371/journal.pone.0065821368186723785454 Search in Google Scholar

22. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013;1:54–63.10.1158/2326-6066.CIR-13-0034388597824416729 Search in Google Scholar

23. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233–42.10.1016/j.ejca.2013.02.01523478000 Search in Google Scholar

24. Balermpas P, Rodel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163ţ macrophages in primary tumour and CD11bţ myeloid cells in recurrences. Br J Cancer 2014;111:1509–18.10.1038/bjc.2014.446420008925093488 Search in Google Scholar

25. Gooden MJ, de Bock GH, Leffers N, Daemen T, NijmanHW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105:93–103.10.1038/bjc.2011.189313740721629244 Search in Google Scholar

26. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–7410.1158/1078-0432.CCR-13-3271418500124714771 Search in Google Scholar